We also investigated DDX58 expression, prognosis, and immune cell infiltration in various cancer types through pan-cancer analysis, confirming that DDX58 is a potential therapeutic target for ischemic HF patients at an increased risk of developing cancer. The gene discussed is RIGI; the disease is cancer.